Abstract | BACKGROUND: METHODS: RESULTS: There was a statistically significant improvement in mean Montgomery-Asberg Depression Rating Scale (MADRS) scores at 2 weeks, sustained through the 8 week period. Two-thirds of subjects achieved a response to the treatment (decrease in MADRS score of 250%) and 33% achieved remission (final MADRS score <10) after 8 weeks of therapy. Mean levels of fatigue, as measured by the MADRS lassitude item, significantly decreased at all time points with a mean 38% decrease from baseline to 8 weeks. CONCLUSION:
|
Authors | Karen K Miller, Roy H Perlis, George I Papakostas, David Mischoulon, Dan V Losifescu, Danielle J Brick, Maurizio Fava |
Journal | CNS spectrums
(CNS Spectr)
Vol. 14
Issue 12
Pg. 688-94
(Dec 2009)
ISSN: 1092-8529 [Print] United States |
PMID | 20394176
(Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Androgens
- Antidepressive Agents
- Testosterone
|
Topics |
- Administration, Cutaneous
- Adult
- Androgens
(administration & dosage, blood)
- Antidepressive Agents
(pharmacology)
- Depression
(drug therapy, physiopathology)
- Dose-Response Relationship, Drug
- Drug Synergism
- Female
- Humans
- Middle Aged
- Psychiatric Status Rating Scales
- Radioimmunoassay
(methods)
- Regression Analysis
- Testosterone
(administration & dosage, blood)
- Time Factors
|